What are the long term risks of taking sandostatin for acromegaly?

How common are long-term side effects with Sandostatin?

Long-term use of octreotide, the active ingredient in Sandostatin, can lead to gallbladder problems including stones and sludge. This occurs because the drug slows digestion and alters bile flow. Many patients develop asymptomatic gallstones after years of treatment, but some require surgery.

How does Sandostatin affect glucose levels over time?

Sandostatin inhibits insulin, glucagon, and other hormones involved in carbohydrate metabolism. Long-term monitoring of blood sugar is required because patients can develop diabetes or see their existing diabetes worsen. The drug also slows gastric emptying, which can lead to flatulence, diarrhea, and abdominal pain that persists throughout treatment.

What happens to the pituitary gland and tumor after years of treatment?

Sandostatin shrinks pituitary adenomas in many patients. Tumor shrinkage helps control excess growth hormone, excess IGF-1, and the associated clinical symptoms. Tumor shrinkage is not guaranteed every patient, however, and some tumors grow again when the drug is discontinued.

What cardiovascular risks come with chronic use?

Excess growth hormone in acromegaly already raises cardiovascular risk. Sandostatin improves many cardiovascular parameters by bringing growth hormone and IGF-1 levels back into normal range. The drug itself has almost no direct cardiovascular risk, but when growth hormone levels stay controlled for years, improvements include smaller cardiac muscle,更好 blood pressure, and better cardiac function.

When does Sandostatin stop wirk?

Sandostatin treatment is indefinite for most patients with acromegaly. Treatment is continued as long as it wirks and tolerates. Treatment is discontinued if severe side effects occur or if the tumor grows despite the treatment.